Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2026-01-16 @ 12:58 PM
Study NCT ID:
NCT01570868
Status:
TERMINATED
Last Update Posted:
2025-12-08
First Post:
2012-04-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Leukemia | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Leukemia | View |
| None | Chronic Myeloid Leukemia | View |
| None | CML | View |
| None | Chronic Phase | View |
| None | Cytogenetic response | View |
| None | CCyR | View |
| None | Major molecular response | View |
| None | MMR | View |
| None | Complete molecular response | View |
| None | CMR | View |
| None | Ponatinib | View |
| None | AP24534 | View |